Common Stock, Par Value $0.001 Per Share
- Symbol
- ECOR
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
electroCore, Inc.
ECORNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 6, 2026, electroCore, Inc. (the “Company”) issued a press release (i) announcing its financial results for the second quarter ended June 30, 2026, and (ii) providing guidance for the full year of 2026 and certain periods of 2027. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated by reference.…
Press release in this filing
electroCore Announces Second Quarter 2026 Financial Results →Company context
electroCore, Inc. and its subsidiaries are a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. For more information, visit www.electrocore.com.
Current securities
Recent company filings
- 4 filingSep 10, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders · Regulation FD DisclosureSep 9, 2026
- 10-Q filingAug 6, 2026
- DEF 14A filingJul 20, 2026
- 4 filingJun 12, 2026
Registered securities in this filing
electroCore, Inc. · 8-K · Filed 2026-08-06
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item
2.02 Results of Operations and Financial Condition.
On
August 6, 2026, electroCore, Inc. (the “Company”) issued a press release (i) announcing its financial results for the second
quarter ended June 30, 2026, and (ii) providing guidance for the full year of 2026 and certain periods of 2027. A copy of the press release
is furnished herewith as Exhibit 99.1 and incorporated by reference.
The
information contained in this Item 2.02 and Item 9.01 in this Current Report on Form 8-K, including the accompanying Exhibit 99.1 hereto,
shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings,
unless expressly incorporated by specific reference in such filing.
Filed exhibits (1)
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 electroCore Announces Second Quarter 2026 Financial Results Second quarter 2026 net sales of $9.5 million, an increase of 28% over $7.4 million in the second quarter 2025 Net loss of $3.1 million decreased 17% from prior year with Adjusted EBITDA net loss improving 26% from prior-year period Increasing 2026 revenue guidance to greater than 30% year-over-year growth Company to host a conference call and webcast today, August 6, 2026, at 4:30 pm EDT ROCKAWAY, NJ, August 6, 2026 (GLOBE NEWSWIRE) - electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced financial results for the second quarter ended June 30, 2026. The Company reported quarterly revenue of $9.5 million, an increase of approximately 28% year-over-year, driven by continued growth in U.S. prescription sales in the U.S. Department of Veterans Affairs (“VA”) and direct-to-consumer Truvaga sales. “This quarter marked a new era for our company as we implemented significant changes across our commercial organization to better position us for long-term success,” said Joshua Lev, Interim President and Chief Financia…
Open exhibit ↗